Literature DB >> 1596225

Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2.

.   

Abstract

Between September 1987 and October 1990, 265 eyes with rhegmatogenous retinal detachment and severe (with a classification of at least C-3) proliferative vitreoretinopathy were treated with vitrectomy and randomized to treatment with perfluoropropane gas or silicone oil; 131 eyes had undergone no prior vitrectomy (group 1) while 134 eyes had undergone vitrectomy with intraocular gas tamponade (group 2). At the last examination, there were no differences between perfluoropropane gas and silicone oil in achieving visual acuity greater than or equal to 5/200 (43% vs 45% for group 1, 38% vs 33% for group 2) and complete posterior retinal reattachment (73% vs 64% for group 1, 73% vs 61% for group 2). For group 1 eyes followed up for at least 18 months, there was an advantage favoring perfluoropropane gas in achieving complete posterior retinal reattachment (83% vs 60% at 36 months, P = .045). The rates of reoperation and keratopathy were similar, while hypotony was more prevalent in eyes randomized to perfluoropropane gas (group 2). Regardless of tamponade, groups 1 and 2 had similar anatomic and visual success. However, hypotony was twice as prevalent in group 2 (perfluoropropane), and the prevalence of keratopathy increased with follow-up in group 2 (either tamponade). Either tamponade produced better results than those seen with sulfur hexafluoride gas (Silicone Study Report 1).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596225     DOI: 10.1001/archopht.1992.01080180052028

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  47 in total

1.  Changes in visual acuity, axial length, and refraction after removal of intraocular silicone oil following retinal reattachment surgery in Chinese patients: An open-label, prospective study.

Authors:  An-Huai Yang; Wei Jin; Yi-Qiao Xing
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  Is day-1 postoperative review necessary after pars plana vitrectomy?

Authors:  P Alexander; L Michaels; R Newsom
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

Review 3.  Retinal detachment.

Authors:  David Steel
Journal:  BMJ Clin Evid       Date:  2014-03-03

4.  Outcome of complex retinal detachment surgery after silicone oil removal.

Authors:  Nurten Unlü; Hülya Kocaoğlan; Mehmet A Acar; Müge Sargin; Bekir S Aslan; Sunay Duman
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

5.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

6.  Visual and anatomical outcomes after silicone oil removal in patients with complex retinal detachment.

Authors:  Saeed F Al-Wadani; Marwan A Abouammoh; Ahmed M Abu El-Asrar
Journal:  Int Ophthalmol       Date:  2013-10-04       Impact factor: 2.031

7.  Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?

Authors:  R G Williams; S Chang; M R Comaratta; G Simoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

8.  Postvitrectomy hypotonia: the role of the vitreous and retinochoroidal lesions.

Authors:  H D Schubert; K Kuang; J Fischbarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-06       Impact factor: 3.117

Review 9.  Glaucoma management after vitreoretinal surgeries.

Authors:  Helen L Kornmann; Steven J Gedde
Journal:  Curr Opin Ophthalmol       Date:  2016-03       Impact factor: 3.761

10.  Surgical outcomes of transconjunctival sutureless 23-gauge vitrectomy with silicone oil injection.

Authors:  Tansu Erakgun; Sait Egrilmez
Journal:  Indian J Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.